These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34940833)

  • 1. Development of a Hypoparathyroid Male Rodent Model for Testing Delayed-Clearance PTH Molecules.
    Ramezanipour N; Esfahani SHZ; Eastell R; Newell-Price J; Trevitt G; Ross RJ; Wilkinson IR
    Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34940833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral cinacalcet administration decreases serum ionized calcium and parathyroid hormone concentrations in healthy dogs.
    Clark HE; Trepanier LA; Wood MW
    J Vet Pharmacol Ther; 2024 Jul; 47(4):274-279. PubMed ID: 38563476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
    Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
    Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal parathyroid hormone levels do not exclude permanent hypoparathyroidism after thyroidectomy.
    Promberger R; Ott J; Kober F; Karik M; Freissmuth M; Hermann M
    Thyroid; 2011 Feb; 21(2):145-50. PubMed ID: 21190447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
    Sikjaer T; Amstrup AK; Rolighed L; Kjaer SG; Mosekilde L; Rejnmark L
    J Bone Miner Res; 2013 Oct; 28(10):2232-43. PubMed ID: 23649554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.
    Shimizu M; Joyashiki E; Noda H; Watanabe T; Okazaki M; Nagayasu M; Adachi K; Tamura T; Potts JT; Gardella TJ; Kawabe Y
    J Bone Miner Res; 2016 Jul; 31(7):1405-12. PubMed ID: 26865415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog.
    Bi R; Fan Y; Lauter K; Hu J; Watanabe T; Cradock J; Yuan Q; Gardella T; Mannstadt M
    J Bone Miner Res; 2016 May; 31(5):975-84. PubMed ID: 26678919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Long-Term Cinacalcet Administration on Parathyroid Gland in Hemodialysis Patients with Secondary Hyperparathyroidism.
    Okuno S; Inaba M; Ishimura E; Nakatani S; Chou H; Shoji S; Yamakawa T
    Nephron; 2019; 142(2):106-113. PubMed ID: 30712039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.
    Miller G; Davis J; Shatzen E; Colloton M; Martin D; Henley CM
    Nephrol Dial Transplant; 2012 Jun; 27(6):2198-205. PubMed ID: 22036941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
    Iglesias P; Ais G; González A; Tajada P; García Arévalo C; Fernández Pardo E; Díez JJ
    Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinacalcet in the management of tumor-induced osteomalacia.
    Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
    J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.
    Nemeth EF; Heaton WH; Miller M; Fox J; Balandrin MF; Van Wagenen BC; Colloton M; Karbon W; Scherrer J; Shatzen E; Rishton G; Scully S; Qi M; Harris R; Lacey D; Martin D
    J Pharmacol Exp Ther; 2004 Feb; 308(2):627-35. PubMed ID: 14593085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Therapeutic Approach Using a Calcilytic (AXT914) for Postsurgical Hypoparathyroidism in Female Rats.
    Lim YS; You BH; Kim HB; Lim SH; Song JG; Bae MG; Han HK; Choi YH; Choi HS
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32852547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of AMG 416 and cinacalcet in rodent models of uremia.
    Walter S; Baruch A; Alexander ST; Janes J; Sho E; Dong J; Yin Q; Maclean D; Mendel DB; Karim F; Johnson RM
    BMC Nephrol; 2014 May; 15():81. PubMed ID: 24884838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual parathyroid function in chronic surgical hypoparathyroidism.
    Rudnicki M; Transbøl
    Miner Electrolyte Metab; 1991; 17(5):331-4. PubMed ID: 1819765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
    Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
    Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.
    Henrich LM; Rogol AD; D'Amour P; Levine MA; Hanks JB; Bruns DE
    Clin Chem; 2006 Dec; 52(12):2286-93. PubMed ID: 17105782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral phosphorus supplementation secondarily increases circulating fibroblast growth factor 23 levels at least partially via stimulation of parathyroid hormone secretion.
    Takasugi S; Akutsu M; Nagata M
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(2):140-4. PubMed ID: 24975224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.